MAYZENT is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.1

The summary of product characteristics (SmPC) of MAYZENT can be found in the Downloadable resources section or can be viewed on the emc website by clicking here.


  1. MAYZENT (siponimod) Summary of Product Characteristics.
SIP20-C001 May 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]